Clinical trial

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-01-01

PhasePHASE3

Study timeline

Study start (actual)2021-01-01Date precision: day

Registry last updated2022-06-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2+ Breast Cancerunresolved

Interventions

TrastuzumabDRUG · verified · RxNorm: trastuzumab

PertuzumabDRUG · verified · RxNorm: pertuzumab

Nab paclitaxelDRUG

CapecitabineDRUG · verified · RxNorm: capecitabine

EverolimusDRUG · verified · RxNorm: everolimus

CDK4/6 inhibitorDRUG

AIDRUG

Anti-PD-1 monoclonal antibodyDRUG

Sponsors & collaborators

First Affiliated Hospital Xi'an Jiaotong Universitylead sponsor

Mapped research locations

Xi'anShaanxi, China2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05429684 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.